A roach on a cooler wasn't why a Miami 7-Eleven had to trash bacon and cheeseburgers
Inspectors put two coolers at a Miami 7-Eleven on the Do Not Use list and the trash was the new home for bacon, cheeseburgers, milk, Jamaican meat patties and other food in one of those coolers.
Stop Sale and Stop Use Orders flowed freely from Florida Department of Agriculture Inspector Julio Azpura and inspector trainee Lourdes Chantez Tuesday at the downtown 7-Eleven on the corner of Northeast First Street and Second Avenue.
READ MORE: Pepto Bismol in kitchen. Bugs in rice. Miami restaurants with over 30 violations
▪ 'Tongs used by customers to pick up hot dogs, cheese hamburgers, and a spatula for pizza, as well as tongs used by employees, were not cleaned and sanitized at least every four hours.'
▪ 'Roach crawling on the right side of a self-serve reach-in cooler.'
▪ But, the bigger problem with the reach-in cooler, which should be keeping food at 41 degrees or under, was it measured 44 to 48 degrees.
A Stop Use Order came down on the unit. A barrage of Stop Sales sending all the food in the unit, including yogurt, sandwiches, raw bacon, cheese, watermelon and desserts, into the garbage.
▪ The walk-in cooler had the same problem. So, it makes sense that the milk measured a dangerously balmy 48 degrees and Jamaican beef patties and pizzas came in at 46 to 48 degrees.
All that food got hit with Stop Sales. A Stop Use Order ended the cooler's day.
READ MORE: Unsafe milk, tequeños and cheeseburgers among a Miami 7-Eleven's inspection problems
▪ The handwash sink next to a restroom lacked paper towels or any way to dry hands other than your shirt or flapping. Better than lacking hot water, the deficiency in a prep area handwash sink.
▪ A food service area handwash sink leaked when used.
▪ 'Food employees do not wear effective hair restraints while working with open food items.'
READ MORE: Old food. Misplaced Butt Paste. Bakery roaches. A Broward Winn-Dixie had some issues
▪ The mop sink didn't have an appropriately installed backflow protection device, which is sort of a prophylactic protecting the sink and the room in case a sewage backup threatens to leave the place smelling like fertilizer.
▪ In the back area with that mop sink, 'Soil and food debris were on the floor under and around the reach-in freezers, under bag-in-box soda dispensers, near the warewash sink and underneath the display case.'
▪ No ingredients list — and, thus, no listing of possible allergens for folks with a food allergy — was available for pan de bono, guava pastelitos and other bakery items in the hot case.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register here. "The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas." The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria Complete response (CR) rate of 86.7% (26/30 pts) Of these, 25/26 patients achieving CR remain in CR as of the data cut-off Median time to CR in 120 µg/kg = 80 days Median time to CR in 150 µg/kg = 42 days 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively) Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%) In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab There were no Grade 5 TEAEs observed "We believe these new data are differentiating and further reinforce the potential of ZYNLONTA plus the bispecific glofitamab to improve outcomes for DLBCL patients who need it most," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This early safety and efficacy data support the ongoing expansion of this study to 100 patients at the 150 µg/kg dose of ZYNLONTA plus glofitamab. We look forward to discussing the results with Dr. Alderuccio during our conference call today in addition to the presentation of the data set across two key conferences." This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025. Conference Call InformationTo access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About LOTIS-7LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L/3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 µg/kg and then proceeding to 120 µg/kg and 150 µg/kg. Part 2 includes dose expansion in 2L/2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 µg/kg and 150 µg/kg of ZYNLONTA plus the approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity. For more information about the LOTIS-7 trial, visit (NCT04970901). About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of ZYNLONTA® in combination with the bispecific antibody glofitamab, including the reproducibility and durability of any favorable results initially seen in patients dosed to date, and the Company's research, development and regulatory plans, including the timing and results of clinical trials and the timing and outcome of regulatory submissions. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investor RelationsMarcy GrahamADC 650-667-6450 Media RelationsNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
05-06-2025
- Yahoo
Probiotics can help heal ravaged coral reefs
Probiotics are everywhere, claiming to help us poop, restore gut health, and more. They can also be used to help threatened coral reefs. A bacterial probiotic has helped slow the spread of stony coral tissue loss disease (SCTLD) in wild corals in Florida that were already infected with the disease. The findings are detailed in a study published June 5 in the journal Frontiers in Marine Science and show that applying this new probiotic treatment across coral colines helped prevent further tissue loss. SCTLD first emerged in Florida in 2014. In the 11 years since, it has rapidly spread throughout the Caribbean. This mysterious ailment has been confirmed in at least 20 other countries and territories. Other coral pathogens typically target specific species. SCTLD infects more than 30 different species of stony corals, including pillar corals and brain corals. The disease causes the soft tissue in the corals to slough off, leaving behind white patches of exposed skeleton. The disease can devastate an entire coral colony in only a few weeks to months. The exact cause of SCTLD is still unknown, but it appears to be linked to some kind of harmful bacteria. Currently, the most common treatment for SCTLD is using a paste that contains the antibiotic amoxicillin on diseased corals. However, antibiotics are not a silver bullet. This amoxicillin balm can temporarily halt SCTLD's spread, but it needs to be frequently reapplied to the lesions on the corals. This takes time and resources, while increasing the likelihood that the microbes causing SCTLD might develop resistance to amoxicillin and related antibiotics. 'Antibiotics do not stop future outbreaks,' Valerie Paul, a study co-author and the head scientist at the Smithsonian Marine Station at Fort Pierce, Florida, said in a statement. 'The disease can quickly come back, even on the same coral colonies that have been treated.' Paul and her colleagues have spent over six years investigating whether beneficial microorganisms (aka probiotics) could be a longer lasting alternative to combat this pathogen. Just like humans, corals are host to communities known as microbiomes that are bustling with all different types of bacteria. Some of these miniscule organisms produce antioxidants and vitamins that can help keep their coral hosts healthy. [ Related: Caribbean coral is getting sick and dying. A probiotic could help. ] First, the team looked at the microbiomes of corals that are impervious to SCTLD to try and harvest probiotics from these disease-resistant species. In theory, these could be used to strengthen the microbiomes of susceptible corals. They tested over 200 strains of bacteria from disease-resistant corals and published a study in 2023 about the probiotic Pseudoalteromonas sp. McH1-7 (or McH1-7 for short). Taken from the great star coral (Montastraea cavernosa), this probiotic produces several antibacterial compounds. Having such a stacked antibacterial toolbox made McH1-7 an ideal candidate to combat a pathogen like SCTLD. They initially tested McH1-7 on live pieces of M. cavernosa and found that the probiotic reliably prevented the spread of SCTLD in the lab. After these successful lab tests, the wild ocean called next. The team conducted several field tests on a shallow reef near Fort Lauderdale, focusing on 40 M. cavernosa colonies that showed signs of SCTLD. Some of the corals in these colonies received a paste containing the probiotic McH1-7 that was applied directly to the disease lesions. They treated the other corals with a solution of seawater containing McH1-7 and covered them using weighted plastic bags. The probiotics were administered inside the bag in order to cover the entire coral colony. 'This created a little mini-aquarium that kept the probiotics around each coral colony,' Paul said. For two and a half years, they monitored the colonies, taking multiple rounds of tissue and mucus samples to see how the corals' microbiomes were changing over time. They found that the McH1-7 probiotic successfully slowed the spread of SCTLD when it was delivered to the entire colony using the bag and solution method. According to the samples, the probiotic was effective without dominating the corals' natural microbes. While using this probiotic appears to be an effective treatment for SCTLD among the reefs of northern Florida, additional work is needed to see how it could work in other regions. Similar tests on reefs in the Florida Keys have been conducted, with mixed preliminary results, likely due to regional differences in SCTLD. The team believes that probiotics still could become a crucial tool for combatting SCTLD across the Caribbean, especially as scientists fine tune how to administer them. Importantly, these beneficial bacteria support what corals already do naturally. 'Corals are naturally rich with bacteria and it's not surprising that the bacterial composition is important for their health,' Paul said. 'We're trying to figure out which bacteria can make these vibrant microbiomes even stronger.'
Yahoo
05-06-2025
- Yahoo
Will norovirus surge early again this year? Here's what scientists say
Will the upcoming norovirus season be just as early and active as the past year? While the answer may be anyone's guess right now, federal health officials recently warned that the dominant strain of the contagious virus — the leading cause of vomiting, diarrhea, and foodborne illness in the U.S. — has changed between the 2022-2023 and 2024-2025 seasons. 'GII.17 has caused 75 percent of all norovirus outbreaks during the 2024–25 season so far, thereby replacing GII.4 as the predominant norovirus outbreak strain in the United States,' Centers for Disease Control researchers wrote in an article published this month by the agency's Emerging Infectious Diseases journal. This past season also started at the earlier date of October, as opposed to December. GII.17 also drove a record wave of outbreaks. But, what all of this might mean going forward needs further research. 'Additional sequence analysis of complete GII.17 genomes and identification of cross-protective neutralizing antibodies of GII.17 compared with GII.4 viruses could help clarify whether GII.17 viruses will persist. Continued surveillance is needed to determine if this genotype remains the dominant genotype, as well as whether the norovirus season continues to start earlier than previous years,' they wrote. A spokesperson for the agency told CBS News that there are 'currently insufficient historic data to predict whether norovirus GII.17 will remain the dominant genotype and lead to an earlier onset of the norovirus season later this year.' They pointed to a surge of GII.17 strains in Asia and Europe in 2014 that was followed by no reports of a change to seasonality, and noted that there has been no clear evidence to prove that GII.17's emergence was the cause of a change to the norovirus season last year. Still, this past season reached the worst levels in a decade. There were 91 suspected or confirmed outbreaks during the first week of December, which Yale Medicine said exceeded the number of outbreaks during the same week in any year since 2012. The majority were the GII.7 strain. In years when there is a new strain of the virus, there can be 50 percent more norovirus illness. Cases continued to tick up months into this year. By May 7, there were 2,571 outbreaks. During the same time last year, there were only 1,358. 'The total number of outbreaks reported during the 2024 to 2025 seasonal year is above the range reported during the same period during the 2012 to 2020 and 2021 to 2024 seasonal years,' the CDC said. Cases have fallen markedly since January, and are now at low levels. While the outbreaks occur throughout the year, they are the most common from November to April as people head indoors and it's easier to spread norovirus through infected particles. Anyone who consumes raw shellfish is also at risk of contracting it. Infection can be deadly largely among adults aged 65 and up, but anyone can get sick. Children younger than 5 years old and people with weakened immune systems are more likely to develop severe infections. There are 900 deaths on average each year and between 19 and 21 million illnesses. There's no specific treatment for norovirus, but most people recover with a period of up to three days. 'The norovirus can spread so quickly, but also, as we already talked about, norovirus can be very — it's usually very fast. So yeah, if people are taking care of themselves, we leave them alone,' explained Dr. Joanna Bisgrove, a family physician at Rush University Medical Center. 'But if it keeps going, we're like, maybe this isn't norovirus, and we need to do other things.'
